Conditional expression of human PPARδ and a dominant negative variant of hPPARδ in vivo

Larry G. Higgins, Wojciech G. Garbacz, Mattias C. U. Gustafsson, Nainamalai Sitheswaran, Peter R. Ashby, C. Roland Wolf, Colin N. A. Palmer

    Research output: Contribution to journalArticlepeer-review

    4 Citations (Scopus)


    The nuclear receptor, NR1C2 or peroxisome proliferator-activated receptor (PPAR)-delta, is ubiquitously expressed and important for placental development, fatty acid metabolism, wound healing, inflammation, and tumour development. PPAR delta has been hypothesized to function as both a ligand activated transcription factor and a repressor of transcription in the absence of agonist. In this paper, treatment of mice conditionally expressing human PPAR delta with GW501516 resulted in a marked loss in body weight that was not evident in nontransgenic animals or animals expressing a dominant negative derivative of PPAR delta. Expression of either functional or dominant negative hPPAR delta blocked bezafibrate-induced PPAR alpha-dependent hepatomegaly and blocked the effect of bezafibrate on the transcription of PPAR alpha target genes. These data demonstrate, for the first time, that PPAR delta could inhibit the activation of PPAR alpha in vivo and provide novel models for the investigation of the role of PPAR delta in pathophysiology.

    Original languageEnglish
    Article number216817
    Number of pages12
    JournalPPAR Research
    Publication statusPublished - 2012


    Dive into the research topics of 'Conditional expression of human PPARδ and a dominant negative variant of hPPARδ in vivo'. Together they form a unique fingerprint.

    Cite this